Ventricular Arrhythmia and Cardiac Fibrosis in Endurance Experienced Athletes (VENTOUX).
No Thumbnail Available
All Authors
Javed, W.
Botis, I.
Goh, ZM.
Shabi, M.
Brown, B.
Tomoaia, R.
Farooq, M.
Levelt, E.
Graham, L.
Gierula, J.
LTHT Author
Javed, Wasim
Brown, Benjamin
Farooq, Maryum
Graham, Lee
Greenwood, John
Plein, Sven
Swoboda, Peter
Brown, Benjamin
Farooq, Maryum
Graham, Lee
Greenwood, John
Plein, Sven
Swoboda, Peter
LTHT Department
Cardio-Respiratory
Cardiology
Doctors' Rotation
Cardiology
Doctors' Rotation
Non Medic
Publication Date
2025
Item Type
Journal Article
Observational Study
Observational Study
Language
Subject
Subject Headings
Abstract
BACKGROUND: Sudden cardiac death due to primary arrhythmia is a leading cause of mortality in athletes, predominantly affecting older male athletes. Myocardial fibrosis is strongly associated with arrhythmogenesis in nonischemic cardiomyopathy, but its clinical significance in asymptomatic endurance athletes is unknown. We aimed to investigate whether myocardial fibrosis on cardiovascular magnetic resonance in asymptomatic veteran male athletes was associated with incident ventricular arrhythmia on long-term implantable loop recorder.
METHODS: Prospective observational cohort study involving 106 asymptomatic male competitive cyclists/triathletes (aged >=50 years) who undertook >=10 h/wk of exercise for >=15 years. Exclusion criteria were any preexisting cardiovascular disease. Participants underwent clinical assessment, stress-perfusion late gadolinium enhancement-cardiovascular magnetic resonance, exercise testing, and implantable loop recorder implantation to detect ventricular arrhythmia. Athletes were followed up for the primary end point of incident ventricular arrhythmia.
RESULTS: A total of 50/106 (47.2%) athletes had focal myocardial fibrosis (all nonischemic distribution) on cardiovascular magnetic resonance predominantly affecting the basal inferolateral left ventricular segment. During follow-up (median 720 days), 23/106 (21.7%) athletes experienced >=1 ventricular arrhythmic episode; 3/106 (2.8%) sustained ventricular tachycardia, and 20/106 (18.9%) nonsustained ventricular tachycardia. Myocardial fibrosis (hazard ratio, 4.7 [95% CI, 1.8-12.8]; P=0.002) and greater left ventricular end-diastolic volume indexed (hazard ratio, 1.4 [95% CI, 1.1-1.9]; P=0.02) were associated with an increased risk of incident ventricular arrhythmia, but right ventricular insertion point late gadolinium enhancement was not (hazard ratio, 1.7 [95% CI 0.6-5.1]; P=0.32). Myocardial fibrosis remained predictive after adjusting for left ventricular end-diastolic volume indexed (hazard ratio, 4.7 [95% CI, 1.7-12.7]; P=0.002).
CONCLUSIONS: In male veteran endurance athletes, myocardial fibrosis was independently associated with the onset of ventricular arrhythmia, even after adjusting for left ventricular dilatation. Right ventricular insertion point late gadolinium enhancement was not associated with ventricular arrhythmia. Further studies are needed to establish whether myocardial fibrosis itself is arrhythmogenic or a marker of an underlying cardiomyopathic process.
Journal
Circulation. Cardiovascular imaging